Arca Biopharma | ABIO - Operating Profit


Arca Biopharma reported $-34.43M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Amgen USD 3.83B 130M Mar/2026
Arca Biopharma USD -34.43M 326K Dec/2025
Biogen USD 514.3M 128.8M Mar/2026
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Grifols EUR 320.55M 91.01M Dec/2025
Laboratory Of America USD 410.1M 28.1M Mar/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Otsuka Holdings JPY 118.21B 50.97B Mar/2026
Pfizer USD 4.65B 3.99B Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025